The role of hyperuricemia in development of the cardiovascular diseases

Main Article Content

N. M. Shuba
T. D. Voronova
A. S. Krylova


The article presents recent data on the role of hyperuricemia and the activity of xanthine oxidase in particular in the pathogenesis of cardiovascular diseases development such as arterial hypertension, heart failure, myocardial infarction, caused by a significant increase of hyperuricemia in recent years (USA epidemiological data, 2007–2008). Importance of hyperuricemia level effective control was shown in lowering the incidence of general and cardiovascular death, heart failure, atrial fibrillation and other chronic heart diseases. The significance of selective blockade of xanthine oxidase has been proved for the reduction of uric acid level, especially its high values, in particular in case of renal insufficiency, and also in preventing the development of endothelial dysfunction.

Article Details


hyperuricemia, cardiovascular diseases, xantionxidase, febuxostat, allopurinol


Shuba NM. Hiperurykemiia – multymorbidna patolohiia v revmatolohii. Ukr. revmatoloh. zhurn. [Ukrainian Rheumatology Journal] 2013; 2 (52):14–21. (in Ukr).

Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, Hata H, Shiono M. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). Cardiology. 2015;66:298–303.

Choi HK, Ford ES, Li C. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57:109–115.

Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr. Pharm. Des. 2005;11:4161–4175

Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 2012;11 (8):633–652

Doehner W, Rauchhaus M, Florea VG, Sharma R, Bolger AP, Davos CH, Coats AJ, Anker SD. Uric acid in cachectic and non-cachectic CHF patients—relation to leg vascular resistance. Am. Heart J. 2001;141:792–799.

Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010; 464(7293): 1357–1361.

Emmerson B.T. The management of gout. N. Engl. J. Med. 1996; 334(7):445–451.

Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924–932.

Feig DI, Kang D-H, Johnson RJ. Uric Acid and Cardiovascular Risk. N Engl J Med. 2008;359:1811–1821

George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508–2516.

Harzand A, Tamariz L, Hare JM. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest. Heart Fail. 2012;18:179–182 . 10.1111/j.1751–7133.2011.00262.x.

Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovascular. Ther. 2012;30:217–226.–5922.2011.00277.x.

Hisashi Yamanaka Essence of the Revised Guideline for the Management of Hyperuricemia and Gout. JMAJ. 2012;55(4):324–329.

Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, Ishimoto T, Sautin YY, Lanaspa MA. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62(10):3307–3315.

Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ.role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013; 99:759–766.

Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287–1293.

Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375: 132–140.

Karamanou A, Kallistratos MS, Poulimenos LE. Associations between serum uric acid levels and the incidence of hypertension and atrial fibrillation. J. Hypertension. 2015;33(1):372–373.

Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev. 2011;19:265–271.

Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Arthritis Care Res. 2009;61(7):885–892.

Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis — data from a prospective observational cohort study. Arthritis Res. Ther. 2011;13(2):66.

Krishnan E, Pandya BJ, Lingala B, Hariri A, Dabbous O. Hyperuricaemia and untreated gout arepoor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res. Ther. 2012;14:R.10.

Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, Lin CM, Chen HW, Yu KH Gout: an independent risk factor for all‐cause and cardiovascular mortality Rheumatology (Oxford). 2010;49(1):141–146.

Kuo CF, See LC, Yu KH, Chou IJ, Chiou MJ, Luo SF. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology. 2013;52(1):127–134.

Lottmann K, Chen X, Schadlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr. Rheumatol. Rep. 2012;14(2):195–203.

Love BL, Barrons R, Veverka A, Snider KM. Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy. 2010;30:594–608.

Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, Gao P, Tian XJ, Liu JS, Zhu ZH, Huang K, Zhang C.High Serum Uric Acid and Increased Risk of Type 2 Diabetes: A Systemic Review and Meta-Analysis of Prospective Cohort Studies. PLOS ONE. 2013; 8(2):e56864.

Malik UZ, Hundley NJ, Romero G, Radi R, Freeman BA, Tarpey MM, Kelley EE Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic. Biol. Med. 2011;51:179–184.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–241.

Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Ann. Rev. Immunol. 2009;27:229–265.

Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:991–997.

Nilsson PM, Boutouyrie P, Laurent S.Vascular aging: A tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009; 54(1):3–10.

Noman A, Ang, DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161–2167.

Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S,Kinugawa T, Igawa O, Hisatome I, ShigemasaC , Stefan D. Anker, Doehner W. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ. Heart Fail. 2010;3: 73–81.

Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 2006;58:87–114.

Quiñones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268:1–5

Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, Struthers ADMechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J. Am. Coll. Cardiol. 2011;58:820–828.

Rishette P, Bardin T. Gout. Lancet. 2010;375(9711):318–328.

Rothenbacher D, Kleiner A, Koenig W, Primatesta P, Breitling LP, Brenner H. Relationship between Inflammatory Cytokines and Uric Acid Levels with Adverse Cardiovascular Outcomes in Patients with Stable Coronary Heart Disease. PLOS ONE. 2012; 7(9):e45907.

Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425(6957):516–21.

Stack AG, Hanley A, Casserly LF, Cronin CJ, Abdalla AA, Kiernan TJ, Murthy BV, Hegarty A, Hannigan A, Nguyen HT. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM. 2013;106 (7):647–658.

Zhu Y, Pandva B, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis and Rheumatism. 2011;63(10):3136–3141.

Most read articles by the same author(s)